We just need someone to give NGIO a chance. Ii-Key has never lead to death over control. Or a serious adverse event. It’s all documented in numerous peer reviews with Mittendorf and MD Anderson. Or Dr Treanor. With help from Dr Eagle of Pfizer or GSK. And now NSABP. We have 10 year data in BC and 4 or 5 robust immuno response with efficacy in prostate cancer. What else does BARDA need? Joe has it set for success with the right parties including 3M etc. What can he do better? Nothing. Give us one break. SEC is unresponsive, it’s a shame. One break towards success and it happens.